PON1 and type 2 diabetes mellitus: We have previously shown that HDL from people with Type 2 diabetes but no coronary disease and HDL from people with coronary disease but no diabetes were defective in their capacity to metabolize oxidized-palmitoyl, arachidonyl phosphatidylcholine (ox-PAPC) (a primary pro-inflammatory product of LDL oxidation and PON1 substrate) compared with HDL from control subjects [22].